Veracyte enters the post-earnings stretch with short sellers sitting on a meaningful but stabilising position — a setup where the headline numbers are less interesting than the direction of travel.
Short interest has pulled back slightly this week, down roughly 4.6% over the last five trading days to 9.0% of the free float. That follows a sharp build-up through late April, when shorts jumped from around 7.2% of float in mid-April to nearly 9.4% by April 27 — a gain of roughly two percentage points in less than two weeks. The current level, at $32.97, is still up 14% over the past month in share count terms, so the weekly retreat looks more like a pause than a reversal. Days to cover remain elevated at more than 10 days on the official FINRA count, which underlines just how slowly those shorts could cover if sentiment shifted.
The lending market offers no squeeze pressure. Borrowing costs are low — the rate has drifted to around 0.39%, down close to 20% over the past month and at the lower end of the 30-day range. Availability remains loose by any measure, with the borrow pool far from constrained. Options positioning reinforces that picture. The put/call ratio is running at 0.25, only marginally above its 20-day average of 0.23 and a z-score barely above zero. There is no meaningful hedge demand visible in the derivatives market — a notable contrast to the heavy short positioning in the equity lending market. The two signals pull in different directions: options traders are not particularly cautious, while short sellers have been actively adding exposure.
The Street leans bullish on Veracyte but has trimmed its ambition. Eight analysts carry buy ratings against one outright negative, with a consensus mean target near $46.60 — roughly 41% above the current price. Jefferies initiated coverage in April with a Buy and a $45 target, reinforcing the constructive consensus. But Morgan Stanley, the lone bear, cut its target sharply earlier in the year from $48 to $37 while holding its Underweight rating, arguing that small and mid-cap peers trade at lower EV/sales multiples and that weaker operating margins and free cash flow are credible risks. Bulls counter with the TrueMRD test opportunity, the broader cancer diagnostics franchise, and an enterprise value of around $2.2 billion against estimated revenue of roughly $583 million — an EV/revenue multiple near 3.7x that sits at a meaningful discount to the growth multiple implied by the analyst targets. EPS momentum scores in the 72nd percentile over 90 days, and EPS surprise ranks in the 77th percentile, suggesting the company has been consistently delivering against expectations. The factor picture does have one soft spot: forward EPS growth estimates rank only in the 33rd percentile, which anchors part of the bear case.
Institutional ownership is broad and largely passive, with BlackRock at 16.5% of shares and Vanguard at 10.7%. ARK Investment Management holds just under 5%, making it the most active growth-tilted holder in the top ten. Recent changes at the major holders are modest — State Street added around 617,000 shares in its latest filing, the largest single move among the top ten. Insider activity from March tells a cleaner story: the CEO, CFO, and several senior executives all sold shares on March 4 at prices in the $35-$36 range, a cluster of routine disposals above the current market level. The 90-day net is positive largely because of equity award grants, not open-market purchases.
Q1 results landed on May 5, and with earnings now behind the stock the next focal point shifts to how the TrueMRD pipeline data lands over coming months and whether the revenue trajectory — and specifically margin progress — narrows the gap between where bears think the multiples should be and where bulls think the growth story takes them.
See the live data behind this article on ORTEX.
Open VCYT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
